Kaplan Fox & Kilsheimer LLP
17.01.2024 - 06:25:59Acelyrin (SLRN) Investor Update: Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline
| Kaplan Fox & Kilsheimer LLP Acelyrin (SLRN) Investor Update: Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline 17-Jan-2024 / 06:25 CET/CEST The issuer is solely responsible for the content of this announcement. NEW YORK, NY - (NewMediaWire) - January 16, 2024 - Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of investors that purchased or otherwise acquired Acelyrin, Inc. (“Acelyrin” or the “Company”) (NASDAQ: SLRN) securities between May 4, 2023 and September 11, 2023, inclusive (the “Class Period”). Click Here to Join the Action. If you purchased Acelyrin securities and would like to discuss this notice, your rights, or your interests please click here. You may also contact us by emailing jcampisi@kaplanfox.com or calling (212) 329-8571. If you are a member of the proposed Class, you may move the court no later than January 16, 2024 to serve as a lead plaintiff for the purported class. If you have losses, we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. The Complaint alleges that on May 4, 2023, Acelyrin’s common stock began publicly trading on the Nasdaq Global Select Market (“NASDAQ”) under the trading symbol “SLRN.” The Complaint further alleges that on September 11, 2023, after the markets closed, Acelyrin announced disappointing top-line results from Part B of the Phase 2b/3 trial evaluating izokibep for the treatment of moderate-to-severe HS. Specifically, izokibep failed to show statistically significant reduction in abscesses and inflammatory nodules in patients as compared to placebo. On this news, Acelyrin’s stock price fell $17.19 per share, or 61.61%, over the following two trading sessions, to close at $10.71 per share on September 13, 2023. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in complex litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this notice, your rights, or your interests, please contact: Jeffrey P. Campisi, Esq. KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (212) 329-8571 E-mail: jcampisi@kaplanfox.com Laurence D. King, Esq. KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1560 Oakland, California 94612 (415) 772-4704 Fax: (415) 772-4707 E-mail: lking@kaplanfox.com Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. |
